NovoCure 2024年第四季度GAAP每股收益$(0.61)不及预期$(0.34),销售额$1.6127亿高于预期$1.5781亿

财报速递2025-02-27
NovoCure (纳斯达克代码:NVCR) 报告称季度每股亏损$(0.61),未达到分析师共识预期的$(0.34),差79.41%。 这比去年同期每股亏损$(0.45)下降了35.56%。公司报告季度销售额为1.6127亿美元,高于分析师共识预期的1.5781亿美元,增长2.19%。 这比去年同期1.3378亿美元的销售额增加了20.54%。

以上内容来自Benzinga Earnings专栏,原文如下:

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.34) by 79.41 percent. This is a 35.56 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $161.27 million which beat the analyst consensus estimate of $157.81 million by 2.19 percent. This is a 20.54 percent increase over sales of $133.78 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法